DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/skdhnn/translational_rege) has announced the addition of the "Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features Innovative Stem Cell and Gene Therapy Applications" report to their offering.

More Guidelines Needed to Grow Regenerative Medicine Market, Report Finds

Standardized research guidelines are needed to control and encourage the development of gene therapy and stem cell treatments, according to a new report by healthcare experts GBI Research.

The new report* shows how regenerative medicine is seen as an area with high future potential, as countries need ways to cope with the burden of an aging population.

The stem cell market alone is predicted to grow to around $5.1 billion by 2014, while gene therapy has also shown promise despite poor understanding of some areas of regenerative medicine and a lack of major approvals (the only approvals to date being made in Asia).

Up until now, securing research within clinics has been difficult, with a high number of failures and discontinuations throughout all phases of clinical study. Stem cell therapy uses bone marrow transplants as an established treatment method, but the development of the therapy into further applications and has not yet become common practice.

Similarly, tissue engineering has been successful in the areas of skin and bone grafts, but translation into more complex therapies has been an issue for researchers. Although scientific possibilities are ever-increasing, the true potential of regenerative medicine has yet to be demonstrated fully.

A desire to discover new and innovative technologies has encouraged governments in the UK and Singapore to focus directly on regenerative medicine as a future potential economy booster.

Companies Mentioned:

The rest is here:
Research and Markets: Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features ...

Recommendation and review posted by Bethany Smith

SUNRISE, Fla., June 25, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced today that Kristin Comella, the company's Chief Science Officer presented at the 10th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Yokohama, Japan June 13 - 16, 2012. One of the world's premier stem cell research events, the ISSCR format includes international research and poster presentations from invited speakers, exceptional peer-to-peer learning and unparalleled networking opportunities.

Comella presented a poster on clinical applications of adipose or fat derived stem cells (ADSCs).

The ISSCR annual meeting serves as the largest forum for stem cell and regenerative medicine professionals from around the world. Through lectures, symposia, workshops, and events attendees experience innovative stem cell and regenerative medicine research, advances and what's on the horizon. The meeting features more than 1,000 abstracts, nearly 150 speakers and provides numerous networking and professional development opportunities and social events. For additional information, visit http://www.isscr.org.

Kristin Comella has over 14 years experience in corporate entities with expertise in regenerative medicine, training and education, research, product development and senior management including more than 10 years of cell culturing experience. She has made a significant contribution to Bioheart's product development, manufacturing and quality systems since she joined the company in September 2004.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2011, and its Quarterly Report on Form 10-Q for the quarter ended March 30, 2012.

Excerpt from:
Bioheart's Chief Science Officer Kristin Comella Presents at 10th Annual Meeting of International Society for Stem ...

Recommendation and review posted by sam

What if dying patients waiting for an organ transplant could receive a custom, lab-grown replacement rather than waiting for a donor organ?

To some, this may sound like science fiction -- and in many ways, it still is. But the advances in the field of regenerative medicine that made headlines last week suggest such lab-grown organs may become reality in the future.

One of these advances was Swedish scientists' creation of a custom vein that has carried blood from a little girl's intestines to her liver for a year and counting. In another, a group in Japan successfully implanted lab-grown livers made from human cells into mice -- organs that metabolized drugs the way they would in a human.

And these developments may be just the tip of the iceberg. From skin to blood vessels to solid organs, work is underway to offer more options for patients with faulty or damaged body parts.

Dr. Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine in Winston-Salem, N.C., was part of the first group in the world to successfully implant a lab-grown organ into the human body. Atala's interest in the field began when he was training to become a urologist and saw numerous children who had undergone bladder replacement surgery. Many of them were experiencing leaks, and some even suffered ruptures of their new bladders.

"That's when I really thought, 'Why not try to grow these children new bladders from their own cells?'" Atala said.

Atala collected a small number of cells -- about the size of half a postage stamp -- from the original, inadequate bladders of children with spinal cord birth defects. Each child's own cells were multiplied in the lab and then placed on a biodegradable scaffolding. In seven weeks, the cells had grown to fill in the scaffold, creating a new bladder. The procedure was first performed in 1998, and by 2006 they had seen long-term success of the organs.

"I still hear from some of them occasionally," Atala said. "They are still walking around with their engineered bladders, and they are happy with them."

Since this first foray into growing organs, Atala has been one of the many doctors on the forefront of what some say could one day be a new paradigm in medicine -- growing spare parts from a patient's own cells.

Atala currently heads up more than 300 researchers in the Wake Forest University lab who are working on growing more than 30 different organs and body tissues.

View post:
Lab-Grown Organs May Be the Future

Recommendation and review posted by sam

TAIPEI, June 25, 2012 /PRNewswire-Asia/ -- TaiGen Biotechnology Company, Limited ("TaiGen") and Zhejiang Medicine Company, Limited ("ZMC") today announced that they have signed an exclusive agreement to manufacture and commercialize nemonoxacin, a novel broad-spectrum antibiotic, in China (excluding Hong Kong, and Macau). Nemonoxacin is a novel broad-spectrum non-fluorinated quinolone antibiotic under development for respiratory infections. TaiGen will be responsible for completing the Phase 3 clinical trial for community acquired pneumonia ("CAP") in China. ZMC will be responsible for manufacturing, sales and marketing of nemonoxacin in China through its wholly-owned subsidiary, XinChang Pharmaceuticals. TaiGen will retain full development and commercialization rights outside the licensed territory including Taiwan, the United States, European Union, and Japan. Under the terms of the agreement, TaiGen will receive an upfront payment of US$ 8 million from ZMC and will receive additional milestones as well as royalties on product sales. The term of the agreement is 20 years.

Nemonoxacin has demonstrated efficacy and safety in CAP and diabetic foot infection in multinational and multi-center clinical trials conducted by TaiGen. In particular, nemonoxacin has excellent activity against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant MRSA. Nemonoxacin is taken once-a-day and available in both oral and intravenous formulations. Currently, TaiGen is completing a Phase 3 CAP trial with more than 500 patients from Taiwan and mainland China and expects to file new drug applications in Taiwan and mainland China simultaneously in early 2013.

China is one of the major antibiotic markets in the world. According to IMS, the sales of antibiotics in 2011 were approximately US$ 11 billion (RMB 68 billion) and account for almost 20% of the total pharmaceuticals sales. Rate of antibiotic resistant infections in China is among the highest in the world.

Mr. Li Chun Bo, Chairman of the ZMC, commented, "We are impressed with nemonoxacin's broad spectrum activity towards drug-resistant bacteria, in particular, MRSA, and excellent safety profile. We are excited to establish this partnership with TaiGen because of its reputation as a premier research-based biotech company in Asia. This partnership will break new ground for cross-strait collaboration in the pharmaceutical industry. Nemonoxacin will be a major addition to ZMC's antibiotic product line and significant profit driver".

Dr. Ming-Chu Hsu, President and Chief Executive Officer of TaiGen, said, "China is the world's fastest growing pharmaceutical market. It is poised to overtake Japan as the second largest pharmaceutical market. We are extremely please to establish our nemonoxacin partnership with ZMC, a first-class pharmaceutical company and major player in the Chinese antibiotics market. With nemonoxacin, TaiGen and ZMC together will bring new medicine to treat unmet medical needs in China. This partnership will not only set a new record for pharmaceutical licensing involving a Taiwanese and a mainland Chinese company but hopefully will also become a model of the future collaborations," Dr. Hsu also added, "With the conclusion of the partnership in China, we will actively pursue nemonoxacin licensing discussions in other territories such as European Union."

About Zhejiang Medicine

Zhejiang Medicine Company, Limited is a leading pharmaceutical company in China specializing in sales and distribution of pharmaceuticals and manufacturing of active pharmaceutical ingredients (vitamins and antibiotics). Its sales revenue in 2011 is US $740 million (RMB 4.8 billion). ZMC is a leader in the Chinese antibiotic market with levofloxacin, vancomycin, and teicoplanin in the product line. ZMC's Lai Li Xin, a branded levofloxacin, is one of the top selling antibiotics in China with 2011 sales exceeding US $110 million (RMB 735 million). In addition to pharmaceuticals sales, ZMC is also known for its manufacturing quality. Its vancomycin active pharmaceutical ingredient has obtained GMP qualification from US Food and Drug Administration (FDA) and exported to western countries. ZMC is publicly listed in the Shanghai Stock Exchange (600216) and has a market capitalization of RMB 11 billion.

About TaiGen Biotechnology

TaiGen Biotechnology is a leading research-based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, mainland China. TaiGen has full discovery research capacity in Taiwan and clinical development in mainland China/Taiwan/US. In addition to nemonoxacin, TaiGen has two other in-house discovered new chemical entities in clinical development under IND with US FDA: TG-0054, a chemokine receptor antagonist for stem cell transplantation and chemosensitization, in Phase 2 and TG-2349, a HCV protease inhibitor for treatment of chronic hepatitis infection, in Phase 1. Both TG-0054 and TG-2349 are currently in clinical development in the US.

Disclaimer

View original post here:
TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine

Recommendation and review posted by simmons

BOSTON, MA--(Marketwire -06/25/12)- When it comes to disease, few are crueler than ALS. Approximately 5,600 people in the U.S. are diagnosed with ALS each year. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their death. The life expectancy is 2-5 years from the time of diagnosis. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. Most ALS patients expire from suffocation while suffering no cognitive depreciation.

Brainstorm Cell Therapeutics Inc., trading on the Over the Counter Bulletin Board in the United States, is leading the fight to finding a cure for ALS with its NurOwn proprietary technology. The NurOwn technology is changing the field of regenerative medicine by reprogramming bone marrow derived from mesenchymal stem cells into neuron-supporting cells. The axon terminals (nerve cells ending) will take up neurotrophic factors secreted by the transplanted cells into the muscles or the spinal cord and transport them back into cell bodies within the spinal cord. This will prevent further degeneration of the neuronal cells. Although the primary purpose of the Phase I/II trial being conducted at the prestigious Hadassah Medical Center in Jerusalem is to ensure safety and tolerability, initial data has shown efficacy. Professor Eldad Melamed, the lead investigator of the trial, said, "There have been no significant side effects in the initial patients we have treated with BrainStorm's NurOwn technology. In addition, even though we are conducting a safety trial, the early clinical follow up of the patients treated with the stem cells shows indications of beneficial clinical effects, such as an improvement in breathing and swallowing ability as well as in muscular power. I am very excited about the safety results, as well as these indications of efficacy, we are seeing. This may represent the biggest hope in this field of degenerative diseases, like ALS." Dr. Adrian Harel, CEO of Brainstorm, indicated trial data from the first cohort of 12 patients with ALS will be made available to the public sometime in July 2012.

Sai Rosen, Director for Stem Cell Media, LLC, observed, "Brainstorm's early clinical results showed a marked improvement in breathing. An arterial blood gas (ABG) test measures the levels of oxygen and carbon dioxide in the blood to determine how well the lungs are working and according to the initial data the patients showed improved ABG."

It is expected that a Phase II/III ALS trial application will be filed with the FDA in the United States in the second half of 2012. Brainstorm recently received FDA Orphan Drug Designation for its NurOwn cell therapy for ALS in the U.S. The trial site in the U.S. will be conducted at Massachusetts General Hospital (MGH) and is expected to begin late 2012.

The Company is well positioned financially to see the ALS trial through proof of concept. Dr. Harel has arranged a $10MM stock purchase agreement along with non-dilutive grant monies from the Office of the Chief Scientist (OCS) in the amount of approximately $350,000. The yearly grant for 2012 is $1,100,000 (~4.2 M NIS). Dr. Harel commented, "We are thankful to the OCS for its continued support of our Research and Development program. The non-dilutive capital that we are receiving from the OCS will help move forward our NurOwn technology as a potential new treatment standard for patients with Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)."

Brainstorm's flagship NurOwn technology is also being applied to adult stem cell therapies to treat a variety of debilitating neurodegenerative diseases, such as Parkinson's Disease (PD), Multiple Sclerosis (MS) and spinal cord injuries.

About Stem Cell Media, LLC. We are the world's only online discussion forum dedicated to Stem Cell investors. http://www.investorstemcell.com

http://investorstemcell.com/stem-cell-research/disclaimer/

Read more from the original source:
From the Hands of Angels: Brainstorm Cell Therapeutics Inc.

Recommendation and review posted by simmons

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/skdhnn/translational_rege) has announced the addition of the "Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features Innovative Stem Cell and Gene Therapy Applications" report to their offering.

More Guidelines Needed to Grow Regenerative Medicine Market, Report Finds

Standardized research guidelines are needed to control and encourage the development of gene therapy and stem cell treatments, according to a new report by healthcare experts GBI Research.

The new report* shows how regenerative medicine is seen as an area with high future potential, as countries need ways to cope with the burden of an aging population.

The stem cell market alone is predicted to grow to around $5.1 billion by 2014, while gene therapy has also shown promise despite poor understanding of some areas of regenerative medicine and a lack of major approvals (the only approvals to date being made in Asia).

Up until now, securing research within clinics has been difficult, with a high number of failures and discontinuations throughout all phases of clinical study. Stem cell therapy uses bone marrow transplants as an established treatment method, but the development of the therapy into further applications and has not yet become common practice.

Similarly, tissue engineering has been successful in the areas of skin and bone grafts, but translation into more complex therapies has been an issue for researchers. Although scientific possibilities are ever-increasing, the true potential of regenerative medicine has yet to be demonstrated fully.

A desire to discover new and innovative technologies has encouraged governments in the UK and Singapore to focus directly on regenerative medicine as a future potential economy booster.

Companies Mentioned:

More:
Research and Markets: Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features ...

Recommendation and review posted by simmons

NEW YORK, June 25, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a cell therapy company, today announced that it has been awarded a two year grant totaling $595,252 for the "Development of Human, Autologous, Pluripotent Very Small Embryonic Like (VSELs) Stem Cells as a Countermeasure to Radiation Threat" from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). This peer reviewed grant was awarded to support research to be headed by Denis O. Rodgerson, Ph.D., Director of Stem Cell Science for NeoStem and Mariusz Ratajczak, M.D., Ph.D., who is the head of the Stem Cell Biology Program at the James Graham Brown Cancer Center at the University of Louisville and co-inventor of VSELTM Technology.

This award will fund studies to investigate the potential of very small embryonic-like stem cells as a countermeasure to radiological and nuclear threat. The product candidate, which is an autologous stem cell therapy derived from the patient's own stem cells, will be developed to rescue patients who have been exposed to radiation due to nuclear accident or terrorist threat and to treat cancer patients who have undergone radiation therapy and who consequently have compromised immune systems. The award includes $295,252 for the first year and $300,000 for the second year of the project.

Dr. Denis O. Rodgerson, Director of Stem Cell Science for NeoStem, said, "We are very excited to add radiation treatment to the growing list of indications for which our VSELTM Technology is being evaluated. Those exposed to acute high-dose radiation have compromised immune systems such that the virulence and infectivity of biological agents is dramatically increased. Death can occur within 1-6 weeks following radiation exposure. Currently there is only one intervention that saves a fatally irradiated person -- a rescue through stem cell transplantation. VSELs might be an ideal cell therapy to regenerate the body's immune system and repair other tissues damaged by radiation exposure. Most importantly, early studies show VSELs are resistant to lethal radiation which destroys other immune system restoring stem cells in the body, making autologous treatment post-exposure possible."

Dr. Robin L. Smith, Chairman and CEO of NeoStem, added, "NeoStem is pleased that the NIAID is funding this cutting edge technology that we hope will reinvent the treatment landscape for acute radiation syndrome. We plan to continue to pursue NIH SBIR grants to fund our VSEL technology platform development with non-dilutive capital."

About VSELTM Technology

NeoStem has a worldwide exclusive license to VSELTM Technology. Research by Dr. Mariusz Ratajczak, M.D., Ph.D., and others at the University of Louisville provides compelling evidence that bone marrow contains a heterogeneous population of stem cells that have properties similar to those of an embryonic stem cell. These cells are referred to as very small embryonic-like stem cells. This finding opens the possibility of capturing some of the key advantages associated with embryonic stem cells without the ethical or moral dilemmas and without some of the potential negative biological effects associated with stem cells of embryonic derivation. The possibility of autologous VSEL treatments is yet another important potential benefit to this unique population of adult stem cells. VSELTM Technology offers the potential to go beyond the paracrine effect, yielding cells that actually differentiate into the target tissue creating true cellular regeneration.

About NeoStem, Inc.

NeoStem, Inc. ("we," "NeoStem" or the "Company") continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. Our January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") provides NeoStem with a foundation in both manufacturing and regulatory affairs expertise. We believe this expertise, coupled with our existing research capabilities and collaborations, will allow us to achieve our mission of becoming a premier cell therapy company. Our PCT subsidiary's manufacturing base is one of the few current Good Manufacturing Practices ("cGMP") facilities available for contracting in the burgeoning cell therapy industry. Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and Amorcyte is enrolling patients for a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. We also expect to begin a Phase 1 clinical trial by 2012/2013 to investigate AMR-001's utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is engaged in collaboration with Becton-Dickinson that is exploring the earlier stage clinical development of a T-cell therapy for autoimmune conditions. In addition, our pre-clinical assets include our VSELTM Technology platform as well as our MSC (mesenchymal stem cells) product candidate for regenerative medicine.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements

Visit link:
NeoStem Awarded NIAID Research Grant for the Development of VSEL Technology for Radiation Exposure

Recommendation and review posted by simmons

24-06-2012 10:46 This video was uploaded from an Android phone.

View original post here:
ADHD gene research - Video

Recommendation and review posted by Bethany Smith

Cambridge UK personalised medicines pioneer Horizon Discovery has established three new Centres of Excellence (CoE) for rAAV gene editing.

The Babraham Institute will use Horizons rAAV gene editing technology to understand the different PI3K isoforms and other components of the PI3K signaling networks. PI3K enzymes are critical regulators involved in many cellular responses.

Also through the CoE program, Horizon will support Dana-Farber Cancer Institute and the University of Liverpool in its application of Horizons propriety gene engineering technology, GENESIS, to generate human isogenic cell lines incorporating genes involved in the development of specific diseases, with a focus on cancer.

The Dana-Farber CoE will focus on epigenetic mechanisms involved in the differentiation of normal stem cells and development of normal tissues, and how abnormalities in this process lead to initiation and progression of tumors. They will also develop isogenic cellular models to understand the roles of specific epigenetic genes and their role in breast cancer.

The University of Liverpool is interested the Ras family of proteins (N-, H- and K-Ras) which are involved in many key cellular processes, and how they produce different biological outputs despite their high degree of identity. The university will produce isogenic cellular models that express different forms of these Ras proteins from their endogenous loci.

Dr Rob Howes, principal scientist, Horizon said: We are delighted these three new world class institutes have joined our Centers of Excellence program.

Horizon is hoping to continue expanding the CoE network through 2012, and we look forward to working with an increasing number of excellent scientific groups.

The new human isogenic cell lines generated by the CoEs will be exclusively licensed to Horizon in return for future product royalties. Horizon will also have an exclusive option to license new intellectual property developed.

This forms part of Horizons strategy to generate at least 2500 new X-MANTM (gene X- Mutant And Normal) models of cancer, neurodegenerative, and cardiovascular disease. These models support drug discovery researchers in their efforts to understand how complex genetic diseases manifest themselves in real patients, and help rationalise many aspects of drug development, reducing the cost of bringing to market new personalised therapies.

The centers are part of the GENESIS Gene Editing Consortium, which includes rAAV GENESIS pioneers the University of Washington, the University of Torino, Johns Hopkins University, the Translational Genomics Institute (TGen), the University of Minnesota, the University of Maryland, Case Western Reserve University and the University of Pittsburgh.

Read this article:
New horizons for gene editing

Recommendation and review posted by Bethany Smith

ZURICH, Switzerland--(BUSINESS WIRE)--

Myriad Genetics GmbH announced today that a presentation entitled Current Variant of Uncertain Significance Rates in BRCA 1/2 and Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) Testing, was presented today at the European Human Genetics Conference in Nurnberg, Germany. The study highlights Myriads best-in-class variant classification process and variant of uncertain significance rate.

Researchers analyzed the variant of uncertain significance rate for the BRACAnalysis test (BRCA 1 and BRCA 2 genes) test as well as the COLARIS test (MLH1, MSH2, MSH6, PMS2 and EPCAM genes). From 2002 to 2012, Myriads overall uncertain variant rate decreased due to significant investments made in the development and application of improved processes and statistical techniques and the implementation of a targeted program designed to gather data on family members. Across all ancestries, the BRCA 1 and BRCA 2 variant of uncertain significance rate declined from 12.8% to 2.9%. Further, the variant of uncertain significance rate for Lynch syndrome, a test analyzing the MLH1, MSH2, MSH6, and EPCAM genes, declined to 6.6% in 2012. The variant of uncertain significance for PMS2 gene test, also for Lynch Syndrome, was 4.0%.

This data underscores the importance of a world-class variant classification program as well as the high level of accuracy and sensitivity of Myriads genetic tests. Further, through the investment in research and development for its existing tests, the Company has deepened its understanding of variants and variant classification. Myriad continues to invest furthering this knowledge base in an effort to provide best-in-class testing to patients globally.

Current tests available in Europe have a very high variant of uncertain significance rate, often 25 to 30 percent, stated Gary King, Executive Vice President of International Operations at Myriad. We are pleased to bring Myriads technology and variant classification program to Europe, to enhance the quality of genetic testing available to patients and physicians.

About Myriad Genetics GmbH

Myriad Genetics GmbH is the international headquarters of Myriad Genetics, Inc., a global molecular diagnostic company. The Company is dedicated to making a difference in patients lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of nine molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a focus on improving an individual's decision making process for monitoring and treating disease. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Companys variant classification program; and the Companys strategic directives under the caption About Myriad Genetics. These forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; the risk that we may be unable to expand into new markets outside of the United States; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services and any future products are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with manufacturing our products or operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of healthcare payment systems; risks related to our ability to obtain new corporate collaborations and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we acquire; the development of competing tests and services; the risk that we or our licensors may be unable to protect the proprietary technologies underlying our tests; the risk of patent-infringement and invalidity claims or challenges of our patents; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading Risk Factors contained in Item 1A in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

See the original post here:
Myriad Presents Variant of Uncertain Significance Rates at European Human Genetics Conference 2012

Recommendation and review posted by Bethany Smith

23-06-2012 15:45 Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for fair use for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use. The video made solely for the purpose of fan use, study, review or critical analysis purposes only. No video for this song has surfaced yet, so being one of my favorite songs ever, I did it as a tribute. I use footage previously uploaded to you tube in which Gene is singing "dance in the street". The clapping is so similar that I couldn't resist to make this video!

Originally posted here:
Gene Vincent

Recommendation and review posted by Bethany Smith

23-06-2012 23:23 Dr Rima Laibow Speaks on Codex Alimentarius Global Eugenics -- Using Medicine To Kill' is a feature length documentary using a collaboration of various materials. It covers topics such as the swine flu, vaccines and vaccinations, quarantine, water, depopulation, eugenics, Monsanto, gm seeds, Agenda 21, and Codex Alimentarius. In 2008, BA Brooks, a director specialized in meanwhile at The New York Film Academy in the creation of digital movies, launched his first exclusive documentary created with videos downloaded from YouTube, a technique that was used successfully in the documentary at hand, Global EUGENlCS -- Using Medicine to Kill, from 2009, which in over two hours of footage, he could afford to treat a wide range of topics: the avian flu and swine and their possible genetic manipulation, the vaccines and the aggressive vaccination campaigns, the origins of AIDS / HIV , martial law, medical news, water, GD Searle and genetically modified food, Agenda 21 -- the imposition of "sustainable development", HR 875 -- the legislation enforcement of the Codex Alimentarius in the US and others, all of which can be grouped under a single logo -- eugenic politics.

Go here to read the rest:
Dr Rima Laibow 4/4 Speaks on Codex Alimentarius - Video

Recommendation and review posted by Bethany Smith

23-06-2012 23:23 Dr Rima Laibow Speaks on Codex Alimentarius Global Eugenics -- Using Medicine To Kill' is a feature length documentary using a collaboration of various materials. It covers topics such as the swine flu, vaccines and vaccinations, quarantine, water, depopulation, eugenics, Monsanto, gm seeds, Agenda 21, and Codex Alimentarius. In 2008, BA Brooks, a director specialized in meanwhile at The New York Film Academy in the creation of digital movies, launched his first exclusive documentary created with videos downloaded from YouTube, a technique that was used successfully in the documentary at hand, Global EUGENlCS -- Using Medicine to Kill, from 2009, which in over two hours of footage, he could afford to treat a wide range of topics: the avian flu and swine and their possible genetic manipulation, the vaccines and the aggressive vaccination campaigns, the origins of AIDS / HIV , martial law, medical news, water, GD Searle and genetically modified food, Agenda 21 -- the imposition of "sustainable development", HR 875 -- the legislation enforcement of the Codex Alimentarius in the US and others, all of which can be grouped under a single logo -- eugenic politics.

Originally posted here:
Dr Rima Laibow 3/4 Speaks on Codex Alimentarius - Video

Recommendation and review posted by Bethany Smith

23-06-2012 23:24 Dr Rima Laibow Speaks on Codex Alimentarius Global Eugenics -- Using Medicine To Kill' is a feature length documentary using a collaboration of various materials. It covers topics such as the swine flu, vaccines and vaccinations, quarantine, water, depopulation, eugenics, Monsanto, gm seeds, Agenda 21, and Codex Alimentarius. In 2008, BA Brooks, a director specialized in meanwhile at The New York Film Academy in the creation of digital movies, launched his first exclusive documentary created with videos downloaded from YouTube, a technique that was used successfully in the documentary at hand, Global EUGENlCS -- Using Medicine to Kill, from 2009, which in over two hours of footage, he could afford to treat a wide range of topics: the avian flu and swine and their possible genetic manipulation, the vaccines and the aggressive vaccination campaigns, the origins of AIDS / HIV , martial law, medical news, water, GD Searle and genetically modified food, Agenda 21 -- the imposition of "sustainable development", HR 875 -- the legislation enforcement of the Codex Alimentarius in the US and others, all of which can be grouped under a single logo -- eugenic politics.

Read the original here:
Dr Rima Laibow 2/4 Speaks on Codex Alimentarius - Video

Recommendation and review posted by Bethany Smith

ScienceDaily (June 24, 2012) Hemimegalencephaly is a rare but dramatic condition in which the brain grows asymmetrically, with one hemisphere becoming massively enlarged. Though frequently diagnosed in children with severe epilepsy, the cause of hemimegalencephaly is unknown and current treatment is radical: surgical removal of some or all of the diseased half of the brain.

In a paper published in the June 24, 2012 online issue of Nature Genetics, a team of doctors and scientists, led by researchers at the University of California, San Diego School of Medicine and the Howard Hughes Medical Institute, say de novo somatic mutations in a trio of genes that help regulate cell size and proliferation are likely culprits for causing hemimegalencephaly, though perhaps not the only ones.

De novo somatic mutations are genetic changes in non-sex cells that are neither possessed nor transmitted by either parent. The scientists' findings -- a collaboration between Joseph G. Gleeson, MD, professor of neurosciences and pediatrics at UC San Diego School of Medicine and Rady Children's Hospital-San Diego; Gary W. Mathern, MD, a neurosurgeon at UC Los Angeles' Mattel Children's Hospital; and colleagues -- suggest it may be possible to design drugs that inhibit or turn down signals from these mutated genes, reducing or even preventing the need for surgery.

Gleeson's lab studied a group of 20 patients with hemimegalencephaly upon whom Mathern had operated, analyzing and comparing DNA sequences from removed brain tissue with DNA from the patients' blood and saliva.

"Mathern had reported a family with identical twins, in which one had hemimegalencephaly and one did not. Since such twins share all inherited DNA, we got to thinking that there may be a new mutation that arose in the diseased brain that causes the condition," said Gleeson. Realizing they shared the same ideas about potential causes, the physicians set out to tackle this question using new exome sequencing technology, which allows sequencing of all of the protein-coding exons of the genome at the same time.

The researchers ultimately identified three gene mutations found only in the diseased brain samples. All three mutated genes had previously been linked to cancers.

"We found mutations in a high percentage of the cells in genes regulating the cellular growth pathways in hemimegalencephaly," said Gleeson. "These same mutations have been found in various solid malignancies, including breast and pancreatic cancer. For reasons we do not yet understand, our patients do not develop cancer, but rather this unusual brain condition. Either there are other mutations required for cancer propagation that are missing in these patients, or neurons are not capable of forming these types of cancers."

The mutations were found in 30 percent of the patients studied, indicating other factors are involved. Nonetheless, the researchers have begun investigating potential treatments that address the known gene mutations, with the clear goal of finding a way to avoid the need for surgery.

"Although counterintuitive, hemimegalencephaly patients are far better off following the functional removal or disconnection of the enlarged hemisphere," said Mathern. "Prior to the surgery, most patients have devastating epilepsy, with hundreds of seizures per day, completely resistant to even our most powerful anti-seizure medications. The surgery disconnects the affected hemisphere from the rest of the brain, causing the seizures to stop. If performed at a young age and with appropriate rehabilitation, most children suffer less language or cognitive delay due to neural plasticity of the remaining hemisphere."

But a less-invasive drug therapy would still be more appealing.

Excerpt from:
Gene mutations cause massive brain asymmetry

Recommendation and review posted by Bethany Smith

23-06-2012 01:57 I have become so worried about my health because without health I will never get to experience the happiness of falling in love. I now do a Roberg test after every gym workout along with a couple of other tests. I also found out my cousin may be having his pacemaker removed from his heart because there is a surgery to correct his heart without the need for this implanted machine. He has had a pacemaker since his early 20s. It is a possibility I could have what my cousin has and that could possibly explain some of my symptoms. I do feel many doctors in Colombia will do a better job at diagnosing and treating someone with my symptoms. I am seriously considering going for examinations in Colombia and may even seek out treatment there or in another country. I do believe a radical and aggressive approach to both my physical and mental health will definitely enable me to find love in life and make massive amount of friends to share my activities with. I get so jealous of seeing guys in the gym with their girlfriend and friends. I just want to be happy and loved. I basically believe I can still be salvaged!

See the original post:
Romberg Test/ Cardiac Pacemaker Removal?/Finding Love in Life/Stem Cell Treatment - Video

Recommendation and review posted by Bethany Smith

22-06-2012 13:13 This is a small group of beating heart cells in a cell culture that was derived from non-embryonic pluripotent stem cells ("induced pluripotent stem cells"). The induced pluripotent stem cells were generated from skin fibroblasts that were isolated from an 87 year old Native American female. This movie was made through a microscope- the entire culture is only about a millimeter (4 hundredths of an inch) across. The cultures were produced by members of the Loring Lab at The Scripps Research Institute in La Jolla, California.

Read this article:
Beating Cardiomyocytes: From skin cells to stem cells

Recommendation and review posted by Bethany Smith

At 84, American political scientist Gene Sharp has seen his lifelong work on nonviolent resistance echo around the world.

STORY HIGHLIGHTS

London (CNN) -- It's a dark January evening, and in an anonymous townhouse near Paddington station, a man is talking about how to stage a revolution.

A young Iranian asks a question: "The youth in Iran are very disillusioned by the brutality of the violence used against them ... It has stopped all the street protest," she says. "What would you say to them? How can they get themselves organized again?"

The man thinks for a moment. He's an unlikely looking radical -- slightly stooped with white hair, his bent frame engulfed by the low chair he's sitting in.

When he opens his mouth to speak, all eyes in the room are fastened on him.

"You don't march down the street towards soldiers with machine guns. ... That's not a wise thing to do.

"But there are other things that are much more extreme. ... You could have everybody stay at home.

"Total silence of the city," he says lowering his voice to a whisper, punctuating the words with his bent hands, as if he's wiping out the noise himself.

"Everybody at home." The man's eyes scan the room. "Silence," he whispers again.

Read this article:
Gene Sharp: A dictator's worst nightmare

Recommendation and review posted by Bethany Smith

ScienceDaily (June 22, 2012) The gene p53 is the most commonly mutated gene in cancer. p53 is dubbed the "guardian of the genome" because it blocks cells with damaged DNA from propagating and eventually becoming cancerous. However, new research led by Ute M. Moll, M.D., Professor of Pathology at Stony Brook University School of Medicine, and colleagues, uncovers a novel role for p53 beyond cancer in the development of ischemic stroke. The research team identified an unexpected critical function of p53 in activating necrosis, an irreversible form of tissue death, triggered during oxidative stress and ischemia.

The findings are detailed online in Cell.

Ischemia-associated oxidative damage leads to irreversible necrosis which is a major cause of catastrophic tissue loss. Elucidating its signaling mechanism is of paramount importance. p53 is a central cellular stress sensor that responds to multiple insults including oxidative stress and is known to orchestrate apoptotic and autophagic types of cell death. However, it was previously unknown whether p53 can also activate oxidative stress-induced necrosis, a regulated form of cell death that depends on the mitochondrial permeability transition pore (PTP) pore.

"We identified an unexpected and critical function of p53 in activating necrosis: In response to oxidative stress in normal healthy cells, p53 accumulates in the mitochondrial matrix and triggers the opening of the PTP pore at the inner mitochondrial membrane, leading to collapse of the electrochemical gradient and cell necrosis," explains Dr. Moll. "p53 acts via physical interaction with the critical PTP regulator Cyclophylin D (CypD). This p53 action occurs in cultured cells and in ischemic stroke in mice. "

Of note, they found in their model that when the destructive p53-CypD complex is blocked from forming by using Cyclosporine-A type inhibitors, the brain tissue is strongly protected from necrosis and stroke is prevented.

"The findings fundamentally expand our understanding of p53-mediated cell death networks," says Dr. Moll. "The data also suggest that acute temporary blockade of the destructive p53-CypD complex with clinically well-tolerated Cyclosporine A-type inhibitors may lead to a therapeutic strategy to limit the extent of an ischemic stroke in patients."

"p53 is one of the most important genes in cancer and by far the most studied," says Yusuf A. Hannun, M.D., Director of the Stony Brook University Cancer Center, Vice Dean for Cancer Medicine, and the Joel Kenny Professor of Medicine at Stony Brook. "Therefore, this discovery by Dr. Moll and her colleagues in defining the mechanism of a new p53 function and its importance in necrotic injury and stoke is truly spectacular."

Dr. Moll has studied p53 for 20 years in her Stony Brook laboratory. Her research has led to numerous discoveries about the function of p53 and two related genes. For example, previous to this latest finding regarding p53 and stroke, Dr. Moll identified that p73, a cousin to p53, steps in as a tumor suppressor gene when p53 is lost and can stabilize the genome. She found that p73 plays a major developmental role in maintaining the neural stem cell pool during brain formation and adult learning. Her work also helped to identify that another p53 cousin, called p63, has a critical surveillance function in the male germ line and likely contributed to the evolution of humans and great apes, enabling their long reproductive periods.

Dr. Moll's Cell study coauthors include: Angelina V. Vaseva and Natalie D. Marchenko, Department of Pathology, Stony Brook University School of Medicine; Kyungmin Ji and Stella E. Tsirka, Department of Pharmacological Sciences, Stony Brook University School of Medicine; and Sonja Holzmann, Department of Molecular Oncology, University of Gottingen in Germany.

Share this story on Facebook, Twitter, and Google:

Read more:
Most commonly mutated gene in cancer may have a role in stroke

Recommendation and review posted by Bethany Smith

TAMPA Imagine being able to use a person's unique genetic code to find the right treatment for heart failure, asthma or even the dreaded common cold.

That's the focus of Dr. Stephen Liggett, one of the newest additions to the University of South Florida's Morsani College of Medicine.

Liggett, 57, began work this month as director of the USF Health Personalized Medicine Institute. He is a national leader in the emerging field and has attracted millions in research dollars from the National Institutes of Health.

One of his first orders of business will be to collaborate with Dr. Leslie Miller, head of the USF Health Heart Institute, which this spring received $8.9 million in state and county funding to begin developing genomics-based personalized approaches to cardiovascular care.

Liggett comes to USF from the University of Maryland, where he was a professor of medicine and physiology and director of its cardiopulmonary genomics program.

We caught up with Liggett during his first week on the job:

What is personalized medicine?

It's the use of information obtained from an individual's genetic code, or genome, to tailor their medical care. There are three areas where genomic information is particularly useful:

The prediction of whether a person is at risk for developing a disease.

The ability to predict the course, or degree of severity, of a disease in patients.

View post:
National leader in personalized medicine heads new institute at USF Health

Recommendation and review posted by Bethany Smith

23-06-2012 01:57 I have become so worried about my health because without health I will never get to experience the happiness of falling in love. I now do a Roberg test after every gym workout along with a couple of other tests. I also found out my cousin may be having his pacemaker removed from his heart because there is a surgery to correct his heart without the need for this implanted machine. He has had a pacemaker since his early 20s. It is a possibility I could have what my cousin has and that could possibly explain some of my symptoms. I do feel many doctors in Colombia will do a better job at diagnosing and treating someone with my symptoms. I am seriously considering going for examinations in Colombia and may even seek out treatment there or in another country. I do believe a radical and aggressive approach to both my physical and mental health will definitely enable me to find love in life and make massive amount of friends to share my activities with. I get so jealous of seeing guys in the gym with their girlfriend and friends. I just want to be happy and loved. I basically believe I can still be salvaged!

More here:
Romberg Test/ Cardiac Pacemaker Removal?/Finding Love in Life/Stem Cell Treatment - Video

Recommendation and review posted by sam

22-06-2012 13:13 This is a small group of beating heart cells in a cell culture that was derived from non-embryonic pluripotent stem cells ("induced pluripotent stem cells"). The induced pluripotent stem cells were generated from skin fibroblasts that were isolated from an 87 year old Native American female. This movie was made through a microscope- the entire culture is only about a millimeter (4 hundredths of an inch) across. The cultures were produced by members of the Loring Lab at The Scripps Research Institute in La Jolla, California.

Read the original:
Beating Cardiomyocytes: From skin cells to stem cells

Recommendation and review posted by sam

More Photos

Click thumbnails to enlarge

Some of the automated sampling equipment in the Rensselaer Stem Cell Research Center in Troy. Some of the automated sampling equipment in the Rensselaer Stem Cell Research Center in Troy. (Mike McMahon / The Record)

By Danielle Sanzone dsanzone@troyrecord.com Twitter.com/DanielleSanzone

State Department of Health Commissioner Nirav Shah, left, and Rensselaer Polytechnic Institute President Dr. Shirley Ann Jackson, right, announce the opening of the Rensselaer Center for Stem Cell Research during a forum at the colleges Troy campus Friday. (Mike McMahon / The Record)

TROY During a Rensselaer Polytechnic Institute forum on Friday, dozens were able to see their first baby picture: a single cell that eventually multiplied, in part due to stem cells, into an organism with trillions of cells.

That, to me, is the most amazing thing in the study of biology, said Glenn Monastersky, director of the Rensselaer Center for Stem Cell Research.

Visit link:
VIDEO: Stem cell research facility to open at Rensselaer Polytechnic Institute

Recommendation and review posted by simmons

FOR THE PAST decade, two things have consumed large chunks of Malvern native Tom Kramer's time.

The first is his training regimen. Kramer, 46, is a practicing triathlete who will compete Saturday morning in the eighth annual Philadelphia Insurance Triathlon in Fairmount Park.

The second is the search for a bone-marrow match for his wife Pam, also a triathlete, who was diagnosed with a rare form of leukemia in 2000 and eventually willl need a bone marrow transplant.

At some point, Kramer made a creative decision to have those cumbersome obligations intersect. Desperate to spread the word about the importance of registering as a bone-marrow donor he estimates only 9 million people are registered Kramer embarked on a four-event quest over the span of 8 months to raise awareness.

"It was just me in the beginning," he said. "All I had was a banner and some testing kits."

Kramer completed a marathon, two Ironman half-triathlons and a full Ironman triathlon. Eventually his effort gained steam, finally culminating last year when the Kramers incorporated their hard work into the non-profit Racing to Register.

Using endurance sports as a platform, Racing to Register aims to enlarge the pool of potential donors for blood cancer patients in need of lifesaving bone marrow or stem cells.

"We think that the endurance part the reason we chose that platform is that you have to have a lot of endurance to go through that kind of treatment," Kramer said. "There is that marriage there if we can put ourselves through this, you can register."

Athletes that who join Team RTR complete the donor registration process and, in return, the program facilitates their endurance training through coaching, discounted gear and more.

While his wife's illness is what got him started, Kramer says the event has grown into something much bigger. With more than 2,100 registrants, RTR has produced four potential matches.

Read the original post:
Husband competes to raise awareness about bone-marrow registration

Recommendation and review posted by Bethany Smith

BANGALORE, June 22, 2012 /PRNewswire/ --

Adding an impetus to the already existing image of Bangalore being a healthcare destination of India, Columbia Asia Referral Hospital, Yeshwanthpur (CARHY), announced comprehensive bone marrow transplant (stem cell transplant) service on Thursday. This facility will give hope to many cancer patientsin and around Bangalore as there are very few hospitals in South India providing allogeneic transplant, which involves using stem cellsfrom a donor with a similar genetic makeup.

The bone marrow transplant (BMT) service will have a team of medical experts including clinical hematologist, oncologist, and other qualified doctors from allied specialties like pediatrics, infectious disease specialist and trained nurses for stem cell transplant, state-of-the-art HEPA filtered room, ICU, 24 hrs blood bank services and radiology services for providing comprehensive care during stem cell transplant.

Addressing the media, Dr. Nandakumar Jairam, Chairman and Group Medical Director, Columbia Asia Hospitals,said, "We are happy to announce allogenic bone marrow transplant service at our hospital in Yeshwanthpur, over and above the existing autologous transplant service. This will enhance comprehensive bone marrow transplant treatment delivery; a dire need for the people of Karnataka and neighbouring states. This will also help many international patients who look for such a treatment in India."

"This facility is dedicated to providing end-to-end services including expert counsel from a clinical hematologist and an entire team of doctors and nurses providing the latest in medical advances to those suffering from blood cancer and some non-cancerous conditions affecting thebone marrow," said Dr. Satish, Consultant in Clinical Hematology, Columbia Asia Hospitals.

"Bone marrow transplant, also called hematopoietic stem cell transplant (HSCT), is a treatment optionfor certain cancers. With this launch, Columbia Asia Referral Hospital Yeshwanthpur becomes one among the very few centers in India to offer allogeneic bone marrow transplants. Till now, we were doing only autologous transplants which involved the usage of the patient's own stem cells. Now, we will be able to manage conditions like high risk leukemia's, myelomas and lymphomas," said Dr Satish.

"Some of the most effective treatments for cancer such as chemotherapy and radiation are toxic to the bone marrow.The marrow produces different cells that make up the blood such as red blood cells, white blood cells and platelets. The stem cells from the bone marrow are extracted before the administration of high dose chemotherapy and then reintroduced or transplanted to the patient so that blood cell production process is re-established in the bone marrow," addedDr Neelesh Reddy, Consultant Medical Oncology, Columbia Asia Hospitals.

In fact earlier stem cells were collected only from the bone marrow in the hip bones under general anesthesia. However with advanced technology and medical supervision stem cells can now be collected from peripheral blood after giving injections. Stem cells are then harvested by simple procedure called apheresis, (in the same way as dialysis is done) and the rest of the blood is returned to the person.

Continued here:
Columbia Asia Referral Hospital, Yeshwantpur Announces a Comprehensive Bone Marrow Transplant Service

Recommendation and review posted by Bethany Smith